Enterprise Value
139.8M
Cash
201.9M
Avg Qtr Burn
-46.63M
Short % of Float
25.49%
Insider Ownership
4.75%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details Rare diseases, Pulmonary arterial hypertension, Lung disease | Phase 3 Initiation | |
GB004 (Oral HIF-1α stabilizer) Details Ulcerative colitis | Failed Discontinued | |
GB1275 (Oral CD11b modulator) Details Solid tumor/s, Esophageal cancer, Cancer, Gastric cancer | Failed Discontinued | |
Failed Discontinued |